CERO THERAPEUTICS HOLDINGS, INC. 8-K

What Happened
CERO Therapeutics Holdings, Inc. (CERO) filed a Form 8-K (Item 3.01) reporting that, after appealing, the Nasdaq Listing and Hearing Review Council on January 29, 2026 affirmed a Nasdaq Hearing Panel decision to delist the company’s securities and suspend trading. The Panel originally determined to delist and suspend trading on October 29, 2025, with the suspension effective at the opening of trading on October 31, 2025.

Key Details

• Nasdaq Hearing Panel issued the delisting/suspension determination on October 29, 2025.
• Trading suspension was effective at the opening of trading on October 31, 2025.
• CERO appealed the Panel’s decision to the Nasdaq Listing and Hearing Review Council.
• The Council affirmed the Panel’s decision on January 29, 2026, as reported in the Form 8-K filed Feb 3, 2026.

Why It Matters
A confirmed Nasdaq delisting and trading suspension is material for investors because it removes the company’s shares from a major exchange, which can significantly reduce liquidity, market visibility, and ease of trading. Investors should monitor CERO’s subsequent filings and company communications for information on next steps (such as potential transfer to an over‑the‑counter market, re-listing efforts, or other developments).